Skip to main content
Chongqing Lummy Pharmaceutical Co.,Ltd. logo

Chongqing Lummy Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 300006 ISIN · CNE100000H10 LEI · 300300OAF31S686JTM48 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,072 across all filing types
Latest filing 2026-05-15 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300006

About Chongqing Lummy Pharmaceutical Co.,Ltd.

https://www.cqlummy.com

Chongqing Lummy Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and distribution of a diverse range of pharmaceutical products. The company's portfolio primarily focuses on anti-infective agents, including cephalosporin antibiotics, as well as treatments for cardiovascular, gastrointestinal, and endocrine disorders. Lummy Pharmaceutical operates integrated production facilities for both Active Pharmaceutical Ingredients (APIs) and finished dosage forms. Its core competencies include advanced chemical synthesis and the development of specialized drug delivery systems. The company emphasizes innovation in therapeutic areas such as metabolic diseases and systemic anti-infectives, aiming to provide high-quality medical solutions through rigorous quality control and modern manufacturing standards.

Recent filings

Filing Released Lang Actions
关于全资子公司获得化学原料药上市申请批准通知书的公告
Regulatory Filings Classification · 75% confidence The document is a formal announcement by the company’s board disclosing that its wholly‐owned subsidiary has received regulatory approval for a chemical API listing application from the National Medical Products Administration. It contains no financial statements or management discussion, nor is it a notice of dividends, earnings release, or M&A activity—it is a general regulatory/compliance announcement. Therefore, it falls into the fallback category Regulatory Filings (RNS).
2026-05-15 Chinese
关于参与投资设立创业投资基金的进展公告
Capital/Financing Update Classification · 80% confidence The document is a corporate announcement by Chongqing Laimei Pharmaceutical Co., Ltd about the progress of its external investment in the establishment of a venture capital fund, including fund registration completion and details of the investment commitment. This is neither a financial report, proxy statement, nor legal proceeding, but rather an update on a capital-related activity—specifically the company’s deployment of capital into a fund. Therefore it best fits the “Capital/Financing Update” category.
2026-05-11 Chinese
董事会关于会计政策变更合理性的说明
Board/Management Information Classification · 95% confidence The document is a statement from the company's board regarding the reasonableness of a change in accounting policy. It references a board meeting and explains the rationale behind the accounting policy change, emphasizing compliance with stock exchange rules and company bylaws. The document is short (476 characters) and does not contain financial statements or detailed financial data. It is an announcement related to board decisions rather than a full management report or audit report. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by the board.
2026-03-18 Chinese
关于2025年度拟不进行利润分配的专项说明
Notice of Dividend Amount Classification · 95% confidence The document is an official announcement from Chongqing Laimei Pharmaceutical Co., Ltd. regarding the 2025 annual profit distribution plan, specifically stating that no profit distribution (no cash dividends, no stock dividends, no capital reserve conversion) will be made for the year 2025. It includes details about the board meeting approving the proposal, the company's financial situation (negative distributable profits), and compliance with relevant laws and stock exchange rules. The document is relatively short (2281 characters) and focuses on the profit distribution plan rather than presenting full financial statements or comprehensive financial analysis. It is not a full annual report or interim report but an announcement about the dividend decision and related shareholder meeting matters. This fits the category of Notice of Dividend Amount (DIV), which covers announcements of dividend amounts, payment dates, and related details for shareholders, including announcements of no dividend.
2026-03-18 Chinese
2025年年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled as an audit report for the fiscal year 2025 of Chongqing Laimei Pharmaceutical Co., Ltd. It contains detailed auditor opinions, audit basis, key audit matters, and extensive financial statements including consolidated balance sheet, income statement, cash flow statement, and changes in equity. The presence of an auditor's opinion, detailed audit procedures, and comprehensive financial data indicates this is a standalone audit report rather than a full annual report or other filing. The document length is substantial (15,000 characters), and it contains the full audit report text, not just an announcement or certification. Therefore, the document fits the category of Audit Report / Information (AR).
2026-03-18 Chinese
内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled '内部控制审计报告' which translates to 'Internal Control Audit Report'. It is issued by an accounting firm (重庆康华会计师事务所) and addresses the effectiveness of internal control over financial reporting as of December 31, 2025. The content includes auditor responsibilities, management responsibilities, and an audit opinion on internal control effectiveness. The document is 1398 characters long, which is relatively short and focused solely on internal control audit results, not a full annual report or financial statements. This matches the definition of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles. It is not an announcement or certification letter, but the actual audit report. Therefore, the correct classification is AR with high confidence.
2026-03-18 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.